Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NBTX
NANOBIOTIX S.A.
NASDAQ
$41.23
▼ DOWN 8.70% (-3.93)

KEY STATISTICS

Market Cap$2.09 B
52w High$57.14
52w Low$8.03
Dividend Yield—
Frequency—
P/E-69.67
Volume164.84K
Shares Out.50.60M

COMPANY

LEADERSHIP

Laurent Levy
CHIEF EXECUTIVE
Laurent Levy

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 11, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
97

PRICE TARGET

Target High$46.00
Target Low$30.00
Target Median$38.00
Target Consensus$38.00

UPCOMING EARNINGS

DateSep 29, 2026
DayTuesday
Rev. Est.$27.25M
SEP
29
TUE

PRICE

$41.23 ▼ DOWN 8.70% (−$3.93)
$40.50$42.00$43.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM41.23

About Nanobiotix S.A.

https://www.nanobiotix.com ↗

Nanobiotix S.A., a Paris-based biotech founded in 2003, develops cancer treatments like NBTXR3, a nanoparticle therapy for various cancers, with a partnership with LianBio for commercialization in Asia.

INDUSTRY

Biotechnology

A PRODUCT NANOBIOTIX S.A. IS KNOWN FOR

NBTXR3 (JNJ-1900)
NBTXR3 (JNJ-1900)

NBTXR3 is a hafnium oxide nanoparticle-based radioenhancer injected into tumors to amplify radiotherapy's cancer-killing effects while sparing healthy tissue, currently in multiple clinical trials.

Revenue by Products

IconPRODUCTQ2-2021
Other Sales$5K
Services$5K

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
APIE
0.01% · 1.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
11.79%
HOLDERS
20
TOP 12 OF 20 · RANKED BY POSITION SIZE
Johnson & Johnson
5.6M sh · $106.23M
Blackrock Inc.
239.0K sh · $1.2M
Morgan Stanley
36.3K sh · $1.12M
Millennium Management LLC
16.9K sh · $390.01K
Optiver Holding B.V.
16.2K sh · $375.12K
Geode Capital Management, LLC
10.2K sh · $192.38K
Marshall Wace, Llp
9.5K sh · $219.64K
Ubs Group AG
5.6K sh · $171.54K
Bnp Paribas Arbitrage, Snc
3.6K sh · $83.23K
Royal Bank Of Canada
2.6K sh · $61K
Rhumbline Advisers
2.3K sh · $54.14K
Eversource Wealth Advisors, LLC
882 sh · $46.5K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
NEUTRAL 1
BUY 1
3 GRADES IN THE LAST 12 MONTHS
Leerink Partners OUTPERFORM UBS NEUTRAL Guggenheim BUY

SECTORS PEERS

PEERPRICE
GHRS$27.94COMPARE
TYRA$24.94COMPARE
KURA$12.66COMPARE
SVRA$5.26COMPARE
ABUS$5.07COMPARE
SPRY$5.89COMPARE
RZLT$4.62COMPARE
EYPT$4.48COMPARE